{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:17:36Z","timestamp":1792513056467,"version":"4.5.0"},"reference-count":30,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"6","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Precision Oncology"],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:sec><jats:title>PURPOSE<\/jats:title><jats:p> Oncogenic fibroblast growth factor receptor (FGFR) gene alterations have been described in patients with cholangiocarcinoma (CCA). This post hoc analysis assessed progression-free survival (PFS) in patients who had received first- or second-line systemic therapy for advanced\/metastatic CCA before enrollment in the phase II FIGHT-202 study (ClinicalTrials.gov identifier: NCT02924376 ). <\/jats:p><\/jats:sec><jats:sec><jats:title>PATIENTS AND METHODS<\/jats:title><jats:p> Patients with locally advanced or metastatic CCA with FGFR2 fusions\/rearrangements (n = 107), other FGF\/FGFR alterations (n = 20), or no FGF\/FGFR alterations (n = 18) and documented disease progression after at least one systemic cancer therapy before enrollment in FIGHT-202 were assessed. Prior therapy and disease response data were collated from electronic case report forms. PFS was calculated for each prior line of systemic cancer therapy. <\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p> Among patients with FGFR2 fusions\/rearrangements, other FGF\/ FGFR alterations, and no FGF\/ FGFR alterations, respectively, the median PFS with prior first-line systemic therapy was 5.5 months (95% CI, 4.0 to 8.0; n = 102), 4.4 months (2.7 to 7.1; n = 19), and 2.8 months (1.6 to 11.3; n = 16); the median PFS with prior second-line systemic therapy was 4.2 months (3.0 to 5.3; n = 39), 3.0 months (1.1 to 9.9; n = 8), and 5.9 months (2.4 to 12.5; n = 6). The median PFS was 7.0 months (4.9 to 11.1) for patients with FGFR2 fusions\/rearrangements (n = 65) with second-line pemigatinib received during the FIGHT-202 trial. <\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSION<\/jats:title><jats:p> In patients with CCA and FGFR2 fusions or rearrangements, second-line treatment with pemigatinib may be associated with longer PFS compared with second-line treatment with systemic therapy received before study enrollment; however, a prospective controlled trial is required to confirm this. The results support the therapeutic potential of pemigatinib previously demonstrated in FIGHT-202. <\/jats:p><\/jats:sec>","DOI":"10.1200\/po.21.00414","type":"journal-article","created":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T19:59:41Z","timestamp":1652299181000},"update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":26,"title":["Progression-Free Survival in Patients With Cholangiocarcinoma With or Without <i>FGF\/FGFR<\/i> Alterations: A FIGHT-202 Post Hoc Analysis of Prior Systemic Therapy Response"],"prefix":"10.1200","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6871-2333","authenticated-orcid":false,"given":"Kristen","family":"Bibeau","sequence":"first","affiliation":[{"name":"Incyte Corporation, Wilmington, DE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0659-229X","authenticated-orcid":false,"given":"Luis","family":"F\u00e9liz","sequence":"additional","affiliation":[{"name":"Incyte Biosciences International S\u00e0rl, Morges, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine F.","family":"Lihou","sequence":"additional","affiliation":[{"name":"Incyte Corporation, Wilmington, DE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haobo","family":"Ren","sequence":"additional","affiliation":[{"name":"Incyte Corporation, Wilmington, DE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1522-8054","authenticated-orcid":false,"given":"Ghassan K.","family":"Abou-Alfa","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"Weill Medical College, Cornell University, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"b1","doi-asserted-by":"publisher","DOI":"10.21037\/jgo.2016.08.12"},{"key":"b2","doi-asserted-by":"publisher","DOI":"10.1097\/MOG.0000000000000611"},{"key":"b3","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32803"},{"key":"b4","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2011-301748"},{"key":"b5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0908721"},{"key":"b6","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29471"},{"key":"b7","doi-asserted-by":"publisher","DOI":"10.7150\/jca.37610"},{"key":"b8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00027-9"},{"key":"b9","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32463"},{"key":"b10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0115383"},{"key":"b11","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0078"},{"key":"b12","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26890"},{"key":"b13","doi-asserted-by":"publisher","DOI":"10.1200\/PO.17.00080"},{"key":"b14","doi-asserted-by":"crossref","first-page":"e0231877","DOI":"10.1371\/journal.pone.0231877","volume":"15","author":"Liu PCC","year":"2020","journal-title":"PLoS One"},{"key":"b15","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30109-1"},{"key":"b16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.4086"},{"key":"b17","volume-title":"PEMAZYRE (Pemigatinib) Prescribing Information"},{"key":"b18","volume-title":"Pemazyre (Pemigatinib) European Medicines Agency"},{"key":"b20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.3_suppl.303"},{"key":"b21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.4089"},{"key":"b22","first-page":"200","volume":"112","author":"Lamarca A","year":"2020","journal-title":"J Natl Cancer Inst"},{"key":"b23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.4591"},{"key":"b24","doi-asserted-by":"publisher","DOI":"10.4251\/wjgo.v12.i1.83"},{"key":"b25","first-page":"408","volume":"5","author":"Rogers JE","year":"2014","journal-title":"J Gastrointest Oncol"},{"key":"b26","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14063"},{"key":"b27","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu162"},{"key":"b28","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2019.01.001"},{"key":"b29","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00486-1"},{"key":"b30","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2020-0429"},{"key":"b31","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.04.012"}],"container-title":["JCO Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/PO.21.00414","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T11:04:20Z","timestamp":1653822260000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/PO.21.00414"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["10.1200\/PO.21.00414"],"URL":"https:\/\/doi.org\/10.1200\/po.21.00414","relation":{},"ISSN":["2473-4284"],"issn-type":[{"value":"2473-4284","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"2021-09-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-04","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e2100414"}}